[go: up one dir, main page]

PE20160244A1 - Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos - Google Patents

Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos

Info

Publication number
PE20160244A1
PE20160244A1 PE2016000243A PE2016000243A PE20160244A1 PE 20160244 A1 PE20160244 A1 PE 20160244A1 PE 2016000243 A PE2016000243 A PE 2016000243A PE 2016000243 A PE2016000243 A PE 2016000243A PE 20160244 A1 PE20160244 A1 PE 20160244A1
Authority
PE
Peru
Prior art keywords
pai
antibodies
plasminogen activator
same
antibodies against
Prior art date
Application number
PE2016000243A
Other languages
English (en)
Inventor
Philip Janiak
Dorothea KOMINOS
Han Li
Duffieux Francis
Daveu Cyril
Alla Pritsker
Nicolas Baurin
Ryan Morgan Christopher
Magali Mathieu
Alexey Rak
Grailhe Patrick
Bruno Poirier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20160244A1 publication Critical patent/PE20160244A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

La invencion proporciona anticuerpos que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (PAI-1). La invencion tambien proporciona composiciones farmaceuticas, asi como acidos nucleicos que codifican anticuerpos anti-PAI-1, vectores de expresion recombinantes y celulas hospedantes para preparar tales anticuerpos, o fragmentos de los mismos. Tambien se proporcionan metodos de uso de anticuerpos para modular la actividad de PAI-1 o detectar PAI-1, ya sea in vitro o in vivo. Ademas la descripcion proporciona metodos de produccion de anticuerpos que se unen especificamente a PAI-1 en el estado conformacional activo
PE2016000243A 2013-08-13 2014-08-13 Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos PE20160244A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361865451P 2013-08-13 2013-08-13
EP14305757 2014-05-22

Publications (1)

Publication Number Publication Date
PE20160244A1 true PE20160244A1 (es) 2016-05-10

Family

ID=56194112

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000243A PE20160244A1 (es) 2013-08-13 2014-08-13 Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos

Country Status (17)

Country Link
US (4) US9845363B2 (es)
JP (5) JP6696899B2 (es)
KR (1) KR20160035077A (es)
CN (2) CN112142845A (es)
BR (1) BR112016002753A2 (es)
CL (1) CL2016000324A1 (es)
CR (2) CR20190319A (es)
DO (1) DOP2016000042A (es)
EA (1) EA033403B1 (es)
ES (1) ES2770507T3 (es)
HK (1) HK1221725A1 (es)
MX (2) MX2016001851A (es)
PE (1) PE20160244A1 (es)
PH (1) PH12016500239A1 (es)
SG (1) SG10201710013RA (es)
TN (1) TN2016000048A1 (es)
UA (1) UA118267C2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112142845A (zh) * 2013-08-13 2020-12-29 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
CA3008694C (en) 2015-12-18 2022-11-29 Talengen International Limited Use of plasminogen for preventing or treating diabetic nerve injury and related disorders thereof
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
JP6783870B2 (ja) 2015-12-18 2020-11-11 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 心血管病を予防及び治療するための新しい方法
JP2019500426A (ja) 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
WO2018107701A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种新的降血糖和提高糖耐量的药物
CN108210895A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防动脉粥样硬化及其并发症的药物及其用途
WO2018107700A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗病理性肾组织损伤的方法
CN108210892A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肝纤维化的药物及其用途
CN110114082A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗脂肪代谢紊乱及其相关病症的方法
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
CN110121358A (zh) * 2016-12-15 2019-08-13 泰伦基国际有限公司 一种预防和治疗肺纤维化的方法
CN111344004A (zh) 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN117700548A (zh) 2017-08-03 2024-03-15 艾利妥 抗cd33抗体及其使用方法
SG11202106244RA (en) 2018-12-28 2021-07-29 Catalyst Biosciences Inc Modified urokinase-type plasminogen activator polypeptides and methods of use
WO2021066062A1 (ja) 2019-09-30 2021-04-08 株式会社レナサイエンス 免疫チェックポイント分子の発現抑制剤
KR20220093327A (ko) * 2019-10-28 2022-07-05 모나쉬 유니버시티 플라스미노겐에 결합하기 위한 항체
JP7551750B2 (ja) * 2019-12-05 2024-09-17 シージェン インコーポレイテッド 抗αｖβ６抗体及び抗体薬物コンジュゲート
EP4094776A4 (en) * 2020-02-11 2023-05-17 Talengen International Limited METHODS AND MEDICATIONS FOR THE TREATMENT OF VIRAL PENMONIA
CN111072780B (zh) * 2020-03-24 2020-06-23 深圳汉盛汇融再生医学科技有限公司 白血病干细胞抑制剂及其在治疗慢性粒细胞白血病中的应用
AR122480A1 (es) * 2020-05-21 2022-09-14 Cadila Healthcare Ltd VARIANTE DE LA Fc Y PREPARACIÓN DE LA MISMA
CN114605550B (zh) * 2020-12-08 2023-09-22 东莞市朋志生物科技有限公司 抗ca19-9的抗体、其应用和检测ca19-9的试剂盒
CN114686442B (zh) * 2020-12-31 2023-11-07 广州万孚生物技术股份有限公司 一种杂交瘤细胞株及其应用
CN114686441B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 一种能分泌tPAI-C单克隆抗体的杂交瘤细胞株及其应用
CN115873120B (zh) * 2022-09-08 2025-10-21 厦门英博迈生物科技有限公司 一种纤溶酶α2纤溶酶抑制物复合物抗体及应用
WO2025032553A1 (en) * 2023-08-10 2025-02-13 Cochlear Limited Methods of treating inner ear fibrosis

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DK319685A (da) * 1985-07-12 1987-01-13 Fonden Til Fremme Af Eksperime Monoklonale antistoffer, fremgangsmaade til frembringelse af antistofferne, hybridomaceller, der producerer antistofferne, og anvendelse af antistofferne
US5422245A (en) * 1985-07-12 1995-06-06 Fonden Til Fremme Af Eksperimental Cancerforskning Plasminogen activator inhibitor monoclonal antibodies, hybridomas, monoclonal antibody production and use of the antibodies for assay of the inhibitors
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JP2750732B2 (ja) * 1988-04-04 1998-05-13 帝人株式会社 ヒトプラスミノーゲンアクティベーターインヒビター・１−ヒト組織プラスミノーゲンアクティベーター複合体の免疫学的測定方法
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
EP1149913A1 (en) 1990-11-09 2001-10-31 GILLIES, Stephen D. Cytokine immunoconjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK85193D0 (da) * 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
JPH1014592A (ja) * 1996-07-04 1998-01-20 Tanabe Seiyaku Co Ltd ラットｐａｉ−１に対するモノクローナル抗体
WO1998005787A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
AU2001229441A1 (en) * 2000-01-14 2001-07-24 Tanox, Inc. Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease
AU2002216847A1 (en) 2000-10-26 2002-05-06 K.U. Leuven Research And Development Epitopes of pai-1
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
CA2476761A1 (en) * 2002-02-19 2003-08-28 Vanderbilt University Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20040043026A1 (en) * 2002-05-13 2004-03-04 Tai-Lan Tuan Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
ES2562177T3 (es) 2002-09-27 2016-03-02 Xencor Inc. Variantes de Fc optimizadas y métodos para su generación
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
BRPI0506771A (pt) 2004-01-12 2007-05-22 Applied Molecular Evolution anticorpo, e, composição farmacêutica
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US20090202524A1 (en) 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
TR201807983T4 (tr) 2007-08-29 2018-06-21 Sanofi Sa İnsanlaştırılmış anti-CXCR5 antikorları, deriveleri ve kullanımları.
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
EP2198055A4 (en) * 2007-09-07 2012-04-18 Cisthera Inc HUMANIZED PAI-1 ANTIBODIES
WO2009154026A1 (ja) * 2008-06-20 2009-12-23 国立大学法人岡山大学 石灰化小球に対する抗体及びその用途
US20100254979A1 (en) * 2009-03-06 2010-10-07 Cisthera, Incorporated Humanized PAI-1 Antibodies and Uses Thereof
EP2566514A4 (en) 2010-05-03 2013-11-27 Abbvie Inc METHODS OF INHIBITING FIBROSIS WITH ANTI-PAI-1 ANTIBODIES
CN112142845A (zh) * 2013-08-13 2020-12-29 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途

Also Published As

Publication number Publication date
MX2019008803A (es) 2019-09-16
JP6696899B2 (ja) 2020-05-20
JP6907380B2 (ja) 2021-07-21
EA033403B1 (ru) 2019-10-31
DOP2016000042A (es) 2016-04-04
US20160200831A1 (en) 2016-07-14
JP2023055852A (ja) 2023-04-18
US20190359729A1 (en) 2019-11-28
JP2025011161A (ja) 2025-01-23
JP2020125333A (ja) 2020-08-20
EA201690377A1 (ru) 2016-06-30
TN2016000048A1 (en) 2017-07-05
JP7764565B2 (ja) 2025-11-05
CN112142845A (zh) 2020-12-29
CL2016000324A1 (es) 2016-10-21
JP7568756B2 (ja) 2024-10-16
US20230015181A1 (en) 2023-01-19
SG10201710013RA (en) 2018-01-30
US20180155444A1 (en) 2018-06-07
ES2770507T3 (es) 2020-07-01
JP2021155440A (ja) 2021-10-07
UA118267C2 (uk) 2018-12-26
BR112016002753A2 (pt) 2017-11-21
US9845363B2 (en) 2017-12-19
CR20190319A (es) 2019-08-29
CN105705520A (zh) 2016-06-22
JP7223069B2 (ja) 2023-02-15
PH12016500239A1 (en) 2016-05-16
CN105705520B (zh) 2020-09-25
JP2016529255A (ja) 2016-09-23
KR20160035077A (ko) 2016-03-30
HK1221725A1 (zh) 2017-06-09
CR20160117A (es) 2016-05-20
MX2016001851A (es) 2016-05-16

Similar Documents

Publication Publication Date Title
PE20160244A1 (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
AR090352A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
BR112015022491A2 (pt) variantes de inibidor de tecido de metaloprotease tipo três (timp-3), ácido nucleico isolado, vetor de expressão, célula hospedeira isolada e método para produzir uma muteína de timp-3 recombinante, bem como composição e seu uso
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CO6430456A2 (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
CO6741186A2 (es) Polipéptidos interleuquina-2 mutantes
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
MX2016015952A (es) Constructos de anticuerpo multiespecifico.
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
CL2012001539A1 (es) Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
UY33578A (es) PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
CU20170048A7 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
UY35397A (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
EP4349363A3 (en) Dosing regimens
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
BR112014028951A8 (pt) Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor
AR097319A1 (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos